After covariate matching 4:1 with the ALK fusion-positive cohort (by patient characteristics, tumor type, ECOG PS, number of prior therapies, practice type, and timing of CGP), the matched ALK-WT cohort included 88 patients. This evidence concerns the gene ALK and neoplasm.